b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">29949416</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>05</Month>\n            <Day>22</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>12</Month>\n            <Day>10</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1546-3141</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>211</Volume>\n                    <Issue>2</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>08</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>AJR. American journal of roentgenology</Title>\n                <ISOAbbreviation>AJR Am J Roentgenol</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Neuroendocrine Tumor Therapy: <sup>177</sup>Lu-DOTATATE.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>278-285</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.2214/AJR.18.19953</ELocationID>\n            <Abstract>\n                <AbstractText Label="OBJECTIVE">The purposes of this article are to increase understanding of the concepts of theranostics and peptide receptor radionuclide therapy (PRRT) as they apply to neuroendocrine tumors (NETs); review the key 1, 2, and 3 clinical trial data leading to the approval of <sup>177</sup>Lu-tetraazacyclododecanetetraacetic acid-octreotide (<sup>177</sup>Lu-DOTATATE); and foster understanding of the practical aspects and future directions of PRRT for NETs.</AbstractText>\n                <AbstractText Label="CONCLUSION">In January 2018, <sup>177</sup>Lu-DOTATATE therapy was approved in the United States (previously approved in Europe in September 2017) for adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including those of the foregut, midgut, and hindgut. The results of the phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial show favorable outcomes with respect to the primary endpoint of progression-free survival and a host of secondary objectives, including overall survival, objective response rate, and quality of life measures. Patient selection is based on a number of specific factors and should be sequenced carefully with respect to other available therapies, ideally in multidisciplinary cancer conferences. Establishing the therapy at a new institution can be somewhat involved, but once it is established, the therapy is fairly straightforward to administer and is well tolerated with limited side-effects and toxicity. A number of approaches and issues are still to be worked out, and this therapy will continue to be studied and optimized.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Mittra</LastName>\n                    <ForeName>Erik S</ForeName>\n                    <Initials>ES</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>1 Department of Diagnostic Radiology, Division of Nuclear Medicine, Oregon Health &amp; Science University, 3181 SW Sam Jackson Park Rd, Mail Code L340, Portland, OR 97239.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2018</Year>\n                <Month>06</Month>\n                <Day>27</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>AJR Am J Roentgenol</MedlineTA>\n            <NlmUniqueID>7708173</NlmUniqueID>\n            <ISSNLinking>0361-803X</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D009942">Organometallic Compounds</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>AE221IM3BB</RegistryNumber>\n                <NameOfSubstance UI="C447941">lutetium Lu 177 dotatate</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>RWM8CCW8GP</RegistryNumber>\n                <NameOfSubstance UI="D015282">Octreotide</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>AIM</CitationSubset>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D005770" MajorTopicYN="N">Gastrointestinal Neoplasms</DescriptorName>\n                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>\n                <QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018358" MajorTopicYN="N">Neuroendocrine Tumors</DescriptorName>\n                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n                <QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015282" MajorTopicYN="N">Octreotide</DescriptorName>\n                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009942" MajorTopicYN="N">Organometallic Compounds</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">177Lu</Keyword>\n            <Keyword MajorTopicYN="Y">DOTATATE</Keyword>\n            <Keyword MajorTopicYN="Y">NETTER-1 trial</Keyword>\n            <Keyword MajorTopicYN="Y">neuroendocrine tumors</Keyword>\n            <Keyword MajorTopicYN="Y">peptide receptor radionuclide therapy</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>6</Month>\n                <Day>28</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>5</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>6</Month>\n                <Day>28</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29949416</ArticleId>\n            <ArticleId IdType="doi">10.2214/AJR.18.19953</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'